BioScrip (BIOS) to Release Quarterly Earnings on Thursday

BioScrip (NASDAQ:BIOS) is scheduled to be announcing its earnings results before the market opens on Thursday, March 14th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.

NASDAQ:BIOS opened at $3.21 on Thursday. BioScrip has a 12 month low of $2.31 and a 12 month high of $4.14. The firm has a market cap of $405.89 million, a PE ratio of -7.30 and a beta of 0.69.

Get BioScrip alerts:

Several equities research analysts have recently commented on BIOS shares. BidaskClub downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Saturday, February 23rd. Canaccord Genuity started coverage on shares of BioScrip in a research note on Wednesday, December 12th. They set a “buy” rating and a $5.00 price objective for the company. Lake Street Capital lifted their price objective on shares of BioScrip from $4.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday, December 7th. TheStreet upgraded shares of BioScrip from a “d+” rating to a “c-” rating in a research note on Monday, November 26th. Finally, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. BioScrip has an average rating of “Hold” and an average price target of $4.88.

WARNING: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/4202357/bioscrip-bios-to-release-quarterly-earnings-on-thursday.html.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Article: What is Cost of Debt?